Evidence map›Paper›PMID 38957691›Full record

ArticleOpen forum infectious diseases2024

Tuberculosis and Immune Reconstitution Inflammatory Syndrome in Patients With Inflammatory Bowel Disease and Anti-TNFα Treatment: Insights From a French Multicenter Study and Systematic Literature Review With Emphasis on Paradoxical Anti-TNFα Resumption.

Ariane Amoura, Thomas Frapard, Xavier Treton, Laure Surgers, Laurent Beaugerie, Matthieu Lafaurie, Jean Marc Gornet, Raphaël Lepeule, Aurélien Amiot, Etienne Canouï and 6 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Ariane AmouraService de Médecine Interne, Hôpital Beaujon, Assistance Publique des Hôpitaux de Paris, Clichy, France.ORCID https://orcid.org/0000-0002-9986-4700
Thomas FrapardService de Médecine Intensive et Réanimation, Hôpital Henri Mondor, DHU ATVB, Assistance Publique des Hôpitaux de Paris, Créteil, France.
Xavier TretonInstitut des MICI, Groupe hospitalier privé Ambroise-Paré-Hartmann, Neuilly, France.
Laure SurgersService des Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine, Assistance Publique des Hôpitaux de Paris, Sorbonne Université, Paris, France.
Laurent BeaugerieService de Gastroentérologie, Hôpital Saint Antoine, Assistance Publique des Hôpitaux de Paris, Paris, France.
Matthieu LafaurieService de Maladies infectieuses et Tropicales, Hôpital Saint-Louis-Hôpital Lariboisière, Assistance Publique des Hôpitaux de Paris, Paris, France.
Jean Marc GornetService de Gastroentérologie, Hôpital Saint-Louis-Hôpital, Assistance Publique des Hôpitaux de Paris, Paris, France.
Raphaël LepeuleUnité Transversale de Traitement des Infections, Assistance Publique des Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Créteil, France.
Aurélien AmiotService de Gastroentérologie, Hôpitaux Universitaires Henri Mondor, Assistance Publique des Hôpitaux de Paris, Créteil, France.
Etienne CanouïÉquipe Mobile d'Infectiologie, Assistance Publique des Hôpitaux de Paris, APHP-CUP, Hôpital Cochin, Paris, France.
Vered AbitbolService de gastroentérologie, Hôpital Cochin, Assistance Publique des Hôpitaux de Paris, Université Paris Cité, Paris, France.
Antoine FroissartService de Médecine interne, Centre Hospitalier Intercommunal de Créteil, Créteil, France.
Mathias VidonService de Gastroentérologie, Centre Hospitalier Intercommunal de Créteil, Créteil, France.
Yann NguyenService de Médecine Interne, Hôpital Beaujon, Assistance Publique des Hôpitaux de Paris, Clichy, France.
Agnès LefortService de Médecine Interne, Hôpital Beaujon, Assistance Publique des Hôpitaux de Paris, Clichy, France.
Virginie ZarroukService de Médecine Interne, Hôpital Beaujon, Assistance Publique des Hôpitaux de Paris, Clichy, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The advent of anti-tumor necrosis factor α (anti-TNFα) has revolutionized the treatment of inflammatory bowel disease (IBD). However, susceptibility to active tuberculosis (TB) is associated with this therapy and requires its discontinuation. The risk of immune reconstitution inflammatory syndrome (IRIS) in this population is poorly understood, as is the safety of resuming anti-TNFα. Methods: This French retrospective study (2010-2022) included all TB cases in patients with IBD who were treated with anti-TNFα in 6 participating centers. A systematic literature review was performed on TB-IRIS and anti-TNFα exposure. Results: Thirty-six patients were included (median age, 35 years; IQR, 27-48). TB was disseminated in 86% and miliary in 53%. IRIS occurred in 47% after a median 45 days (IQR, 18-80). Most patients with TB-IRIS (93%) had disseminated TB. Miliary TB was associated with IRIS risk in univariate analysis (odds ratio, 7.33; 95% CI, 1.60-42.82; Conclusions: TB with anti-TNFα treatment is often complicated by IRIS of varying severity. Restarting anti-TNFα is a safe and effective strategy.

Indexed as

immune reconstitution inflammatory syndromeinfliximabparadoxical reactionTNF-α antagoniststuberculosis

Identifiers

PMID38957691
PMCPMC11218776

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.